Data in pharma
The data that runs pharma, from clinical trials to real-world evidence, and the strict governance (GxP, privacy) that makes pharma data unlike data anywhere else.
Pharmaceutical decision-making rests on data spanning drug discovery, clinical trials, regulatory submissions, manufacturing, and commercial performance. This block builds fluency in the data structures unique to the sector: trial datasets, real-world evidence, pharmacovigilance records, and prescription data feeds. You will examine where this data originates, how its quality is assessed and governed, and which benchmarks analysts use to judge data maturity and reliability. The block then turns to the regulatory and privacy architecture governing patient and clinical data, from GxP frameworks to HIPAA and GDPR, and the audit practices that keep data trustworthy across R&D, regulatory, and commercial functions. The goal is practical command of pharma-specific data literacy, not generic data theory.
What you'll master
- Map the core data sources across drug discovery, clinical trials, regulatory filings, and commercial operations
- Evaluate data quality using sector-specific metrics like data completeness, traceability, and audit trail integrity
- Apply key privacy and regulatory frameworks (HIPAA, GDPR, GxP, 21 CFR Part 11) to real pharma data scenarios
- Design and run practical data governance checks and audits for clinical and real-world evidence datasets
Key terms
Modules
Introduces the core data types in pharma and the governance and compliance rules that set the sector apart.
Covers pharma data sources, master data resolution, and metrics for data and evidence quality.
Explains privacy regimes, consent and de-identification, governance operating models, and data audits.
Latest articles
Recent articles from the blog that apply to Pharmaceuticals.
- One HCP, six records: why identity resolution is pharma's most expensive data problemA single cardiologist can exist as six different entities across a pharma company's CRM, claims data, and prescriber analytics systems, and none of them match. Until identity resolution works in practice, every downstream decision, from sampling allocations to pharmacovigilance reporting, is built on a fractured foundation.
- GxP integrity, 21 CFR Part 11, and GDPR: what happens when three regulatory regimes collidePharma CDOs operate at the intersection of three distinct regulatory systems, each with its own logic, its own enforcement body, and its own definition of what a data record actually is. Understanding where those systems conflict, not just where they overlap, is the difference between audit readiness and a consent notice architecture that accidentally destroys your audit trail.
- Privacy-enhancing technologies in practice: the hype is ahead of the implementationPrivacy-enhancing technologies have generated serious boardroom attention, and the underlying science is real. But the gap between pilot programs and production-grade deployment is wider than most CDOs are being told.